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ORAL PRESENTATIONS
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Accuracy of GE digital breast tomosynthesis versus supplementary
mammographic views for diagnosis of screen-detected soft tissue breast
lesions
Eleanor Cornford1*, Anne Turnbull2, Jonathan James1, Rachel Tsang1,
Tayeba Akram2, Helen Burrell1, Lisa Hamilton1, Sarah Tennant1, Mark Bagnall2,
Shama Puri2, Graham Balls3, Yan Chen4, Vivienne Jones5
1Nottingham Breast Institute, Nottingham, UK; 2Royal Derby Hospital, Derby, UK;
3Nottingham Trent University, Nottingham, UK; 4Loughborough University,
Loughborough, UK; 5Northampton General Hospital, Northampton, UK
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Introduction: The aim was to compare the accuracy of standard
supplementary views and GE digital breast tomosynthesis (DBT) for
assessment of soft tissue mammographic abnormalities.
Methods: Women recalled for further assessment of soft tissue
abnormalities were recruited and received standard supplementary views
(typically spot compression views) and two-view GE DBT. The added value
of DBT in the assessment process was determined by analysing data
collected prospectively by unblinded radiologists working up the cases.
Following anonymisation of cases, there was also a retrospective multireader
review. The readers first read bilateral standard two-view digital
mammography (DM) together with the supplementary mammographic
views and gave a combined score for suspicion of malignancy on a five-
point scale. The same readers then read bilateral standard two-view DM
together with two-view DBT. Pathology data were obtained. Differences
were assessed using ROC analysis.
Results: The study population was 342 lesions in 322 patients. Final
diagnosis was malignant in 113 cases (33%) and benign/normal in 229
cases (67%). In the prospective analysis, the performance of two-view DM
plus DBT was at least equivalent to the performance of two-view DM and
standard mammographic supplementary views–area under the curve
(AUC) was 0.946 and 0.922 respectively, which did not reach statistical
significance. Similar results were obtained for the retrospective review–
AUC was 0.900 (DBT) and 0.873 (supplementary views), which did not
reach statistical significance.
Conclusion: The accuracy of GE DBT in the assessment of screen-
detected soft tissue abnormalities is equivalent to the use of standard
supplementary mammographic views.
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Breast screening interval and the characteristics of screen-detected cancers
Carl A Tupper1*, Anthony J Maxwell2,3, Susan Astley2,3, Megan Bydder2,
Soujanya Gadde2, Elaine Harkness2,3, Yit Y Lim2,3, Mary Wilson2, Julie Morris4,5
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Centre and Genesis Prevention Centre, University Hospital of South
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Introduction: There is little evidence regarding the optimum interval
between mammograms in a population breast cancer screening
programme. The UK NHS Breast Screening Programme employs a 3-year
interval, unlike other countries which screen more frequently. This study
uses variations in the screening interval within a single large UK
screening service to examine possible relationships between screening
interval and screen-detected cancer characteristics.
Methods: A total of 1107 women diagnosed with breast cancer on
incident screening over a 5-year period were included. Age, time since last
mammogram and surgical histopathology data (tumour type, size, grade,
nodal stage, receptor status) were recorded. The Nottingham prognostic
index (NPI) was calculated for invasive cancers. Analysis with Spearman’s
rho and Pearson’s correlation was performed.
Results: The median patient age was 63. Most screening intervals were
between 800 and 1200 days. The proportion of women with ductal
carcinoma in situ (DCIS) decreased significantly with increasing screening
interval, from 24/94 (25.5%) for < 2.5 years to 35/240 (14.6%) for ≥3 years
(p = 0.032). No significant associations were found between other tumour
variables and screening interval. The average NPI score was 3.49 with a
Pearson correlation coefficient of −0.032 (p = 0.389).
Conclusion: The findings suggest that there is a significant rate of
progression of DCIS to invasive disease within the current 3-year screening
interval. This, together with the rate and characteristics of interval cancers
(which were not examined in this study), appears to be more important in
determining the optimum screening interval than the characteristics of the
invasive cancers detected by screening.
O3
Breast density measurements with ultrasound tomography: a
comparison with non-contrast MRI
Elizabeth O’Flynn1*, Jeremie Fromageau1, Minty Ledger1, Alessandro Messa1,
Ashley D’Aquino1, Minouk Schoemaker1, Maria Schmidt1, Neb Duric1,2,
Anthony Swerdlow1, Jeff Bamber1
1Insititute of Cancer Research and Royal Marsden Hospital, Sutton, UK;
2Karmanos Institute, Detroit, MI, USA
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Introduction: Ultrasound tomography (UST) is an emerging whole breast
3D imaging technique that obtains quantitative tomograms of speed of
sound (as well as other properties) of the entire breast. The measured
parameter is the volume averaged speed of sound (VASS) [1,2]. It improves
on mammography by measuring density at each voxel and holds promise
as a cheap, patient-acceptable, non-ionising radiation method to evaluate
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density. This study was to evaluate the technique of UST and compare
VASS with percentage water density from non-contrast MRI.
Methods: This single-centre cross-sectional trial had research ethics
committee approval. Fifty healthy volunteers from the Generations study
[3] (median age 40 years, range 30−64 years) underwent bilateral breast
UST. Forty-six underwent MRI using a 2-point Dixon technique [4]. VASS
and percentage water density measurements were evaluated in both
beasts and compared with Pearson’s correlation coefficient.
Results: Mean VASS measurements for the cohort were 1446 ± 148 ms−1
(range 1434−1541 ms). There was high similarity between measurements
from the right and left breasts (1463 ± 29 ms−1, 1459 ± 29 ms−1
respectively (p = 0.516)) (ICC = 0.98). Mean percentage water density for
the cohort was 34.6 ± 14.5% (range 13.5−74.4%) with good right-to-left
consistency (35.7 ± 15.3%, 34.4 ± 14.6% respectively (p = 0.55)). There was
excellent correlation between VASS and percentage water density (r2 =
0.97, p < 0.0001).
Conclusion: UST holds promise as a robust, reliable and accurate
technique to evaluate breast density without the use of ionising radiation
and has additional benefits of lower cost and greater patient acceptability.
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Breast tumour localisation using Iodine seeds in the UK: the first 100 patients
Nidhi Sibal*, Nerys Forester
Newcastle Teaching Hospitals, Newcastle, UK
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Introduction: Wire localization techniques for impalpable breast tumours
require wire placement ideally on the day of surgery. Tumour localization using
iodine-125 seeds allows tumour localization to occur prior to surgery, improving
both work flow dynamics and the patient experience. Newcastle Hospitals Trust
is the first centre in the UK to adopt this technique. Here we present our initial
experience of the first 100 patients to undergo wire-free surgery.
Methods: From September 2014, data were prospectively collected on all
patients undergoing iodine seed tumour localization. Seeds were placed
under ultrasound guidance into tumours identifiable on ultrasound
between 7 and 14 days preoperatively. Seeds were removed with the
tumour after intraoperative localization using a gamma probe.
Results: Our first 100 patients are included in this initial analysis. The
majority of patients had a wide local excision, with 10 undergoing
therapeutic mastectomy. Thirteen patients returned to theatre for positive
margins or completion mastectomy, depending on the final pathology.
No seeds were lost during use. One patient had a second tumour
identified at the time of seed placement which required wire localization.
No radiological complications occurred. Introduction of iodine seeds
improved radiological workflow, with creation of a planned outpatient
‘seed list’, remote from the day of surgery and radiological high demand
times.
Conclusion: Iodine seed tumour localization in the UK is achievable,
patient friendly and has great benefits for radiologists in terms of
department workflow. Noticeably, patients (and surgeons) appear much
more relaxed since the introduction of this technique and initial patient
satisfaction surveys have been positive.
O5
Is surgical diagnostic excision always necessary for solid lesions with atypia?
Nisha Sharma*, Rebecca Millican-Slater, Eldo Verghese
Leeds Teaching Hospital NHS Trust, Leeds, UK
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Introduction: As part of diagnostic work for radiological abnormalities seen
in the breast, there has been an increase in use of vacuum-assisted biopsies
for diagnosis. This allows more tissue to be sampled and therefore leads to a
greater degree of diagnostic accuracy. In addition to diagnosis, in some
centres the same procedure has also been used for removal of the entire
lesion–vacuum-assisted excision (VAE). This is sometimes offered in place of
a diagnostic surgical excision in cases of B3 lesions. We wanted to examine
whether VAE can be a safe alternative for B3 lesion that show atypia.
Methods: We identified all patients, at Leeds Teaching Hospital NHS Trust,
who had undergone a surgical diagnostic excision following a core biopsy
which had revealed the following lesions: fibroadenoma, papilloma or
radial scar with atypia (FEA, AIDP or ISLN) during the period between 2009
and 2013. We reviewed the slides of the core biopsy and the subsequent
excision biopsy to confirm the histological diagnosis.
Results: Twenty-nine cases in total satisfied our inclusion criteria. There
were nine cases of fibroadenomas with ISLN and/or AIDP. None of the cases
showed upgrading of the atypia. There were eight cases of radial scar that
had either ISLN, LCIS, epithelial atypia or AIDP, of which two showed DCIS in
the surgical excision. There were 12 cases of papilloma with either ISLN or
AIDP; of these, five had DCIS on surgical excision.
Conclusion: VAE is safe for fibroadenomas with atypia and radial scars
with atypia provided the periphery can be adequately sampled, to help
diagnose DCIS. Papilloma with atypia requires surgical excision due to
complex histological architecture.
O6
Informed choice and consent among women attending for breast
screening in the UK: data from a qualitative study
Patsy Whelehan1,2*, Andrew Evans1, Gozde Ozakinci2
1University of Dundee, Dundee, UK; 2University of St Andrews, St Andrews, UK
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Introduction: While the concept of overdiagnosis can be difficult to
understand, it has been shown that women wish to be informed about it.
The latest breast screening information leaflet offers considerable detail
about potential benefits and harms of screening, including overdiagnosis.
However, it is unknown how much use women attending for screening
make of the leaflet. We report qualitative findings on informed choice and
consent within the UK breast screening programme.
Methods: Participants were clients and mammographers from breast
screening units in Scotland and London. Semi-structured, in-depth,
individual interviews were conducted and thematic analysis performed.
Results: Twenty-two clients were interviewed, aged 50−72: seven first-
attenders and 15 subsequent, from a range of deprivation categories.
Eighteen mammographer-participants included assistant, registered, and
advanced practitioners, with a wide range of ages and lengths of
experience. Most clients understood that screening aims to detect breast
cancer early to improve the chances of survival. Several were aware of
the possibility of false positive results and the risk of mammography
inducing a cancer. Others could not name any risks of screening. Women
had mostly either skimmed the information leaflet or not read it at all.
Several mammographers recounted experiences where women had
appeared to attend under pressure from others and where severe
challenges existed in ascertaining consent.
Conclusion: These qualitative findings that some women attend for
breast screening with little knowledge of the balance of risks and
benefits, and in some cases may encounter coercion, require further
investigation. New methods of communication may be indicated.
POSTER PRESENTATIONS
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Sensitivity of US and FNAC for staging of the axilla in patients
presenting with symptomatic breast cancer
Diane Lister*, Miaad Al-Attar, Elizabeth Denton, Lisa Grosvenor,
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Introduction: We investigated our sensitivity for axillary node staging, in
patients presenting with symptomatic breast cancer from January to
December 2012.
Methods: Of 430 patients identified, 288 had first-line surgical treatment, 63
had neoadjuvant therapy first. Seventy-nine women were unfit for surgery,
had less aggressive evaluation of the axilla and were excluded from
sensitivity calculations. US axilla ± FNA were performed at presentation.
Nodal disease prevalence, sensitivity for diagnosis and the NPV of our tests
were calculated. In the neoadjuvant cases, pretreatment nodal status was
not accurately known.
Results: The prevalence of nodal metastases in our surgery first cases was 43%
(123/288). Twenty-four per cent of cases were micrometastases (29/123). US
sensitivity for macrometastases was 51% (48/94); 41% including
micrometastases (50/123). FNA sensitivity for macrometastases was 38% (36/94;
35 results C5); 30% (37/123) including micrometastases. Combining all groups,
FNA was definitive (C5 or C2) in 90% (134/149) of cases. The NPV of imaging
was 65% (137/210); 75% (137/183) with micrometastases excluded. The NPV of
a C1/2 result was 72% (28/39) giving a false negative FNA rate of 28%. Of
neoadjuvant cases, FNA was positive in 60% (38/63; 35 results C5), giving a
minimum disease prevalence and diagnostic sensitivity of 60%. Combining
both groups, nodal disease prevalence lies between 46% (161/351) and 53%
(186/351). FNA sensitivity is between 48 and 57% for macrometastases (75/157;
75/132); and 40−46% includingmicrometastases (75/186; 75/161).
Conclusion: Axillary staging depends on both US sensitivity and FNAC
technique. US sensitivity is adversely affected by micrometastases. In our
symptomatic patients, FNA sensitivity for macrometastases lies between
48 and 57%.
P2
Accuracy of axillary nodal ultrasound and ultrasound fine needle aspiration/
core biopsy in the preoperative staging of patients with invasive breast
cancer
William Cheung*, Suzanne McLenachan, Gauripriya Babu, Melanie Smith
Breast Unit, Edinburgh, UK
Breast Cancer Research 2015, 17(Suppl 1):P2
Introduction: Patients with invasive breast cancer undergo axillary
ultrasound ± ultrasound fine needle aspiration (US-FNA)/core biopsy for
preoperative staging depending on the ultrasound appearance. At our
institution, abnormal axillary lymph node assessment includes: a cortical
thickness >3 mm, focal or eccentric cortical thickening, nodal shape
(spherical) and replaced appearance with loss of echogenic nodal
hilum. Our aims were to evaluate the accuracy of preoperative US + US-
FNA/core biopsy for detecting axillary metastatic disease.
Methods: Excluding those patients who underwent neoadjuvant
chemotherapy, we identified 120 patients with invasive breast cancer
between January and December 2013, which yielded axillary node
metastases on final surgical pathology. We performed a retrospective
analysis of the clinical records and used descriptive statistics.
Results: Preoperative US correctly identified 60/120 (50%) patients with
axillary metastatic disease, 42/60 (70%) had subsequent true positive US
biopsies. Of the cases where a biopsy was not performed, 88% (53/60) had
one or two positive nodes confirmed after surgery and 12% (7/60) had at
least three nodes. Thirty-four of 60 (57%) were from the symptomatic
population. Of the total 21 false negative US biopsies from the 18 patients,
81% (17/21) were performed via FNA and 19% (4/21) via core biopsy.
Eleven of 18 (61%) were from the symptomatic population. Twenty-nine of
42 (69%) true positive US biopsies were from the symptomatic population.
Conclusion: The results highlight the need for a review of our biopsy
criteria, which may result in a decrease in our biopsy threshold. An increase
in the use of core biopsies may yield greater accuracy in correctly
identifying axillary nodal disease.
P3
Evaluation of the use of microbubbles in the ultrasound assessment of
the axilla in breast cancer patients
Nisha Sharma*, Isobel Haigh, Rebecca Millican-Slater, Benjamin Dessauvagie
St James’s Hospital, Leeds, UK
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Introduction: Contrast-enhanced ultrasound of the axilla can be used to
identify the axillary sentinel lymph node. We introduced this into our
practice in 2013. During the study period there was an upgrade of our
US equipment. The purpose of our audit was to see the negative
predictive value of CEUS biopsy of the SLN.
Methods: This was a retrospective audit. In total, 110 patients with
invasive breast cancer were identified at the breast MDT. The US core
biopsy, surgical sentinel node biopsy and subsequent axillary histology
were documented.
Results: CEUS was successful in identifying the first draining lymph
node in 88.1% (97/111). Eighty-three of 97 cases (86%) had a definitive
biopsy (B2−B5) result with 13 being malignant and 69 were benign.
Fifteen were non-diagnostic with B1 core biopsy. The prevalence of
axillary metastases at surgery was 31% (30/97) (22 macrometastases, six
micrometastases and two isolated tumour cells) of which 42% were
detected by CEUS, with 100% specificity. Two of the 30 cases were in
palpable, non-sentinel nodes. The negative predictive value of CEUS
with core biopsy is 80% but 90% if only macrometastases are included.
Conclusion: CEUS and biopsy is a promising technique for reducing the
false negative rate of imaging at the time of SLNB. Our numbers are
small and we had a transition to different equipment during the study,
but it is felt that reproducible data comparable with Cox et al. [1] is
achievable.
Reference
1. Cox K, et al: Contrast -enhanced ultrasound biopsy of sentinel lymph
nodes in patients with breast cancer. Implications for axillary metastases
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Use of sulphur hexafluoride microbubbles injection to identify the
sentinel lymph node in breast cancer patients: initial experience in a
UK breast unit
Alice Leaver*, Simon Lowes, Peter Newton, Linsley Lunt, Anuradha Anand,
Linda Hutchinson, Sally Athey, Amanda Jane Potterton, Sheetal Sharma,
Alan Redman
Gateshead Hospitals NHS Trust, Gateshead, UK
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Introduction: In our Trust, all breast cancer patients undergo
preoperative axillary staging with ultrasound. Over the past year we
have introduced intradermal sulphur hexafluoride microbubbles
ultrasound contrast injection to help identify sentinel lymph nodes for a
preoperative needle biopsy in each patient. Only patients with
malignant node morphology on grey-scale ultrasound undergo biopsy
without microbubbles injection.
Methods: Prospective audit of data collated at the time of the
microbubbles procedure together with multidisciplinary meeting
records identified relevant screening and symptomatic patients with
primary breast cancer treatment including axillary node surgery
between 1 July 2014 and 1 July 2015. Descriptive statistics were
performed.
Results: Sixty-four female patients underwent microbubbles injection
and axillary node surgery. Overall combined sensitivity and specificity of
microbubbles ultrasound/biopsy procedure were 67% (8/12) and 100%
(52/52) respectively. Seventy-five per cent of operative sentinel node
biopsies (45/60) showed evidence of previous needle biopsy (four
axillary clearance specimens excluded). Needle biopsy detection of
micrometastatic disease only, shortly after commencing microbubbles
use, led to multidisciplinary meeting consideration of size of needle
biopsy metastasis and ultrasound appearance of sentinel and
surrounding nodes in triage of patients to type of axillary surgery.
Results represent the combined learning curve of seven radiologists.
The procedure was well tolerated by patients and technically easy to
perform. The greatest challenges were optimising ultrasound machines
for microbubbles visualisation, and finding time within busy clinics to
perform the procedure.
Conclusion: In this small patient cohort, introduction of microbubbles
has facilitated reliable and effective identification of the sentinel lymph
node for assessment of morphology on ultrasound and also biopsy.
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Preoperative identification and biopsy of sentinel lymph nodes using
contrast-enhanced ultrasound: the Tunbridge Wells experience
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Introduction: At Maidstone and Tunbridge Wells NHS Trust, all newly
diagnosed breast cancer patients with a normal grey-scale axillary
ultrasound have a procedure to identify and biopsy sentinel lymph nodes
(SLN) using contrast-enhanced ultrasound (CEUS).
Methods: Retrospective data were collected on patients undergoing a
CEUS guided biopsy over a 42-month period at Tunbridge Wells Breast
Clinic (TWBC). We compared the results of the first group of patients
with the most recent to determine the performance of the test over
time.
Results: Between February 2011 and June 2012, 94 patients had a CEUS
guided biopsy of SLN. Twenty patients were excluded; five had
neoadjuvant therapy, five were unfit for surgery, one had an abnormal
grey-scale ultrasound and nine had incomplete data. SLN were
visualised in 92% and 83% had a successful SLN core biopsy. The
sensitivity of the test to detect SLN metastases was 56%, specificity
100%, negative predictive value 86% and prevalence of lymph node
(LN) metastases 27%. Between October 2013 and September 2014, 99
patients had the test. Thirty patients were excluded from the final
analysis. SLN were visualised in 86% and 74% had a successful SLN core
biopsy. The sensitivity was 69%, specificity 100%, negative predictive
value 90% and prevalence of LN metastases 25%.
Conclusion: The percentage of SLN visualised and successfully biopsied
in TWBC decreased between the two study periods. These findings may
represent a normal fluctuation of the test’s performance, be a function
of missing data in retrospective collection or the cumulative ‘learning-
curves’ of newly appointed radiologists. This warrants further analysis.
P6
Correlation of post-neoadjuvant chemotherapy response on MRI with
final histology in breast cancer patients
Anjum Mahatma*, Lyn Jones, Alexandra Valencia
Breast care centre, North Bristol NHS Trust, Bristol, UK
Breast Cancer Research 2015, 17(Suppl 1):P6
Introduction: We used MRI breasts to assess neoadjuvant chemotherapy
response in line with departmental protocol. The aims were to see the
correlation of findings on MRI with final histology in patients with breast
cancer receiving neoadjuvant chemotherapy, and to assess the accuracy
of our reporting and to evaluate the cause for any discordancy.
Methods: Retrospective data collection from March 2012 to May 2014.
Data on 50 consecutive patients, who had both pre and post
neoadjuvant MRIs, were collected. Use of CRIS, NBT PACS and UHB PACS
for reports and image visualisation. Use of Ultra inquires on the intranet
for histopathology reports.
Results: Discrepancy in size of residual tumour between MRI and
histology within 10 mm was considered concordant. Concordant size
between MR and histology = 31/50 (62%). Discordant size between MR
and histology = 19/50 (38%). For complete response: sensitivity = 46%,
specificity = 86%, positive predictive value = 71% (95% CI 45−88%),
negative predictive value = 70% (95% CI 53−82%), accuracy = 70%.
Conclusion: Good specificity but low sensitivity in line with published
literature. The time interval between second MRI and time to surgery did
not affect the ability of MRI to predict response. Presence of DCIS and
LCIS (42%) influenced MRI-histology discrepancy. Hormonal-positive, Her2-
positive and triple-positive were more likely to show size discrepancy
compared with other hormone profiles.
Recommendation: We plan to integrate DWI into our reports to increase
sensitivity.
P7
Use of preoperative breast MRI to determine disease extent
Nicky Dineen*, Jennifer Weeks, Ruxandra Pietrosanu, Karina Cox, Pippa Mills
Maidstone General Hospital, Maidstone, Kent, UK
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Introduction: Breast MRI can be performed in the preoperative workup
of patients with biopsy-proven breast cancer to size lesions, if there is
discrepancy regarding the extent of disease from clinical, mammography
or ultrasound assessment, and to identify multicentric or multifocal
disease. The purpose of breast MRI is to plan the optimum surgical
procedure, thus reducing the local tumour recurrence rate and the need
for the patient to undergo additional surgery.
Methods: In this poster we have reviewed breast MRI examinations from
patients with a new diagnosis of breast cancer, who had a preoperative
MRI.
Results: There were 75 scans in total. Patients who had MRI occult
disease or neoadjuvant chemotherapy were excluded, leaving a total of
51 breast MRI scans. Invasive tumour size and total tumour size (invasive
tumour + DCIS) as seen on MRI were compared with the size reported in
the surgical pathology specimen. There was accurate correlation in
invasive tumour size in 81% and significantly discordant sizing in 19%.
Correlation in overall tumour size including DCIS was 70% and
significantly discordant in 30%. In three patients in whom the total
tumour size was overestimated, the patients consequently had complete
local excision with wide excision margins. In another patient, in whom
the total disease extent was underestimated on MRI, following complete
local excision, repeat surgery was required for positive margins. In these
four patients the MRI was misleading for guiding the optimum surgical
procedure.
Conclusion: MRI tumour size assessment particularly for DCIS should be
interpreted with caution.
P8
MRI evaluation of multifocality and contralateral disease in lobular
breast cancer: what can we learn from one region’s experience?
Claire Magee1,2*, Keith Lowry1
1Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, UK;
2NIMDTA, Belfast, UK
Breast Cancer Research 2015, 17(Suppl 1):P8
Introduction: Invasive lobular cancer has been associated with an
increased risk of multifocal and contralateral disease. The literature
suggests an incidence of contralateral disease as high as 15%. Current
national (NICE) recommendations are that all patients with lobular
carcinoma being considered for breast-conserving surgery have a
preoperative breast MRI. The objective was to identify the rate of
additional MRI-detected multifocal and contralateral disease in patients
with a newly diagnosed lobular cancer to determine whether it is as
high as the literature suggests. Based on our findings we hope to
further explore whether another imaging alternative should be
considered.
Methods: A retrospective search was done on PACS to identify all those
patients in Northern Ireland investigated with bilateral breast MRI for a
newly diagnosed cancer during a 15-month period. MRI findings were
correlated with histopathology records from all regional labs and the data
analysed.
Results: A total of 141 patients had an MRI for biopsy-proven lobular
carcinoma. Within this regional cohort the incidence of additional
contralateral and multifocal disease was 2.13% and 13.4% respectively.
Conclusions: The incidence of contralateral lobular disease is 2.13%,
within our reasonably large study population, significantly less than the
currently cited 15%. Our study does show a significant increase in
detection of multifocal disease in the same breast by MRI. Based on our
results consideration should be given to exploring the use of
tomography or contrast-enhanced mammography prior to MRI to
attempt to detect further disease. This could potentially expedite
patient care.
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Use of MRI to predict response following neoadjuvant chemotherapy
for breast cancer: how accurately can it guide surgical choice?
Sue Tan*, Simon Lowes, Carol Ellen Holmes, Nidhi Sibal, Lesley McLean,
Nerys Forester
Newcastle Teaching Hospitals, Newcastle, UK
Breast Cancer Research 2015, 17(Suppl 1):P9
Introduction: Breast MRI monitors tumour response to neoadjuvant
chemotherapy (NAC) and guides breast-conserving-therapy (BCT). It is
unclear how accurately MRI predicts pathological response. This audit
investigates concordance between MRI findings and final pathology
following NAC.
Methods: Patients undergoing NAC between January 2011 and
December 2014 were retrospectively identified. MRI was performed
before, during and after NAC. At final MRI, response was graded as
radiological complete response (CR no/<5 mm enhancement), partial
response (PR <90% original enhancement), or no response (NR <10%
reduction in enhancement). After surgery, pathological outcomes were no
residual cancer (NRC), <5 mm invasive cancer/DCIS present (PRC), or >5
mm residual invasive cancer (RC). Radiological and pathological responses
were either concordant or discordant.
Results: Forty-six patients had NAC over 4 years (mean age 52 years),
43 IDC; three inflammatory carcinoma (not analysed). Radiological CR was
seen in 19, PR in 18 and NR in six. Pathological outcome was NRC in 10,
PRC in nine, and RC in 24. Responses were concordant in 30/43. BCT was
attempted in 22 patients. Three required mastectomy for margins
(despite two demonstrating radiological CR). MRI correctly predicted
complete pathological response in 7/19 patients. In 12/19 there was
residual disease despite MRI appearances. All six patients with no MRI
response had residual invasive disease. Three patients with a partial MRI
response demonstrated pathological complete response.
Conclusion: MRI during NAC is useful, particularly when the MRI response
is PR or NR. However, a complete radiological response predicts a
complete pathological response in less than 50% of cases. Patients
undergoing BCT following NAC should be aware of the risks of subsequent
surgery.
P10
Is pretreatment assessment of the contralateral breast with MRI useful
following a new diagnosis of invasive lobular cancer?
Harriet Russell1,2*, Rebecca Geach1,2, Iain Lyburn1,2, Helen Massey1,2
1Thirlestaine Breast Centre, Cheltenham, Gloucestershire, UK; 2Cheltenham
Imaging Centre, Cheltenham, Gloucestershire, UK
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Introduction: There is a reported increased incidence of contralateral
disease at presentation of invasive lobular cancer (ILC). In our unit breast
MRI is undertaken to assess the extent of all newly diagnosed ILC. If
mastectomy is planned MRI is still carried out to assess the contralateral
breast–we set out to evaluate this.
Methods: We reviewed 160 reports of consecutive dynamic contrast-
enhanced breast MRIs of newly diagnosed ILC (January 2010−June 2015).
All cases had been double reported according to the BI-RADS lexicon by
two trained readers. We looked at the number of cases of BI-RADS MRM
scores of 3 or above in the contralateral breast, second-look ultrasound
findings, biopsy rate (U/S or MRI guided) and resultant contralateral
cancer detection.
Results: Of the 160 cases, 23 (14.4%) had an indeterminate or suspicious
lesion reported in the contralateral breast. Three of these were
contralateral cancers that had already been diagnosed by conventional
imaging prior to MRI examination. Seventeen (10.6%) had second-look
ultrasound of the contralateral breast: 15 lesions were subsequently
biopsied in 11 women. Following negative second-look ultrasounds, two
women had MRI-guided biopsy. MRI and subsequent work-up identified
three women (1.9%) with previously undiagnosed contralateral
malignancies. These were a 5 mm invasive ductal cancer, a 16 mm DCIS
and a multicentric ILC.
Conclusion: The incidence of ‘conventional imaging occult’ contralateral
disease in ILC may be lower than initially reported. The routine use of
MRI to assess the contralateral breast is potentially questionable.
P11
Comparison of MRI and digital breast tomosynthesis in the
preoperative evaluation of multifocal breast cancer
Bhavna Batohi*, Valeria Vinci, Clare Peacock, Michael Michell, Asif Iqbal,
David Evans, Juliet Morel, Keshthra Satchithananda, Reema Wasan,
Rumana Rahim
King’s College Hospital, London, UK
Breast Cancer Research 2015, 17(Suppl 1):P11
Introduction: Preoperative assessment of tumour extent is crucial in the
management of breast cancer. MRI is currently indicated in cases of
invasive lobular carcinoma on histology, a dense breast parenchymal
pattern on 2D digital mammography (2DDM) or if there is a
discrepancy between the clinical and radiological extent of disease. We
compared the imaging characteristics of multifocal breast cancers on
MRI, digital breast tomosynthesis (DBT), ultrasound and 2DDM to
demonstrate the accuracy of each modality in the assessment of
multifocal cancers.
Methods: A retrospective review of 74 cases over a 4-year period was
conducted. We included all cases whereby MRI or DBT identified two or
more lesions that were considered suspicious or highly suggestive for
malignancy. We compared the sign on MRI (including morphology and
enhancement characteristics) against the lesion detectability on DBT.
The final histology of these lesions obtained following ultrasound-
guided core biopsy, vacuum-assisted MR-guided biopsy or surgical
excision was considered.
Results: There were 142 proven malignancies on histology out of the 74
cases, all of which were detected on MRI. The results of the MRI led to a
change in surgical management in approximately 50% of cases but
overstaged 16% of cases.
Conclusion: MRI is more sensitive than the other three imaging
modalities combined in accurately identifying multifocal breast cancer;
however, DBT is still a useful adjunct in the evaluation of multifocal
disease. There was no correlation between the pathological subtype and
the non-detectability of multifocal cancer on the combined imaging
modalities.
P12
MRI guided breast biopsy: initial experience of service expansion in
West Midlands
Muthyala Sreenivas*, Vandana Gaur
UHCW NHS Trust, Coventry, UK
Breast Cancer Research 2015, 17(Suppl 1):P12
Introduction: At UHCW Hospitals NHS Trust (which is the sole provider
of diagnostic breast MRI for UHCW, South Warwickshire and George
Elliot Hospitals NHS Trusts) the MRI guided breast biopsy service has
been running since June 2011. Initially, the service was offered to
patients imaged at UHCW NHS Trust. With increased experience and
confidence the service is now offered to all the eight NHSBSP screening
sites in the West Midlands. Here we present our experience regarding
the outcomes.
Methods: Since June 2011, 50 cases were referred for MRI guided
breast biopsy of which 10 cases were referred from outside the UHCW
NHS Trust diagnostic imaging cohort. There were three high-risk
screening cases whilst the remaining cases already had diagnosis of
cancer but MRI identified further lesions. All cases were graded B3 or
above on diagnostic imaging. All images were reviewed (obtained via
IEP) and biopsy performed within 10 days of the initial request. Biopsy
samples were sent to local hospitals for pathological analysis.
Results: Forty-eight out of 50 cases were considered for biopsy. Two cases
were deemed benign (one on review of diagnostic MRI and one case on
second-look US). There were 24 malignancies (50 % of all cases). A follow-up
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MRI or surgical excision recommendation was made as necessary for non-
malignant cases in the biopsy report.
Conclusion: MRI guided breast biopsy has been successfully established at
UHCW NHS Trust which currently serves as the regional referral centre in
the West Midlands.
P13
Can public consultation effectively optimise the design of a patient
information leaflet about breast magnetic resonance imaging?
Lyn Jones*, Anna Mankelow, Joanne Robson, Anjum Mahatma,
Alice Pocklington, Alexandra Valencia
Bristol Breast Care Centre at North Bristol NHS Trust, Bristol, UK
Breast Cancer Research 2015, 17(Suppl 1):P13
Introduction: Breast magnetic resonance imaging (MRI) involves multiple
aspects that are unique to a medical environment and may seem
frightening and strange to a person from a non-medical background (the
tunnel, no credit cards, keys or watches, loud noises, intravenous pump
injector). The purpose of an information leaflet is to inform people about
what they should expect, and to prepare them for the experience. During
public consultation about breast MRI, we discovered that women
considered the current information provided by the NHS (from several
different hospitals) to be inadequate. They told us that their experience of
the process of breast MRI had been more distressing that it would have
been had they been better informed. We decided to ask their advice on
the design of an information leaflet to see if it could be optimised to
better prepare women for the experience.
Methods: Public consultation was used to identify aspects of breast MRI
that required explanation in an information leaflet and how they would
like the information presented. We incorporated their suggestions into
our new design and asked for comments at a second public consultation
session.
Results: The need for intravenous access, the tunnel, the nature of the
loud noises that changed during the scan and knowledge that the
radiographers could see and hear them throughout the scan were all
emphasised as requiring explanation. The public suggested the use of
multimedia including links to videos, sounds and personal accounts of
experience.
Conclusion: Our new leaflet has been approved by the public and
patients.
P14
Contrast-enhanced spectral mammography: what is the ‘added value’
in a symptomatic setting? Initial findings from a UK centre
Sarah Tennant1*, Eleanor Cornford1, Jonathan James1, Helen Burrell1,
Lisa Hamilton1, Yan Chen2
1Nottingham University Hospitals NHS Trust, Nottingham, UK;
2Loughborough University, Leicester, UK
Breast Cancer Research 2015, 17(Suppl 1):P14
Introduction: Contrast-enhanced spectral mammography (CESM) is a
new technology. Dual energy acquisitions during one exposure yield two
sets of images: a low energy (LE) set, equivalent to standard full field
digital mammography (FFDM); and a recombined set displaying contrast
uptake. In our symptomatic breast service, specific patients, including
those with a P4/5 clinical abnormality are offered CESM instead of FFDM.
Despite encouraging data from Europe and the USA, there are, until now,
no UK data to support its use in this setting.
Methods: Retrospective multi-reader review of 50 consecutive patients
undergoing CESM. Anonymised LE images were reviewed and given a
score for suspicion of malignancy. At least 3 weeks later, the entire
examination (LE and recombined images) was reviewed. Pathology data
were obtained for all cases. Differences in performance were assessed
using receiver-operative characteristic (ROC) analysis. Sensitivity, specificity
and lesion size (vs. MRI or histopathology) were analysed using a two-way
independent t test.
Results: Fifty females, mean age 49. Thirty-four (68 %) patients had biopsy-
proven malignancy, 16 (32 %) were benign. CESM was more sensitive than
LE alone (94 % vs. 86 %, p <0.025), more specific than LE alone (84 % vs.
63 %, p <0.025) and showed better size estimation (mean size difference
23 % vs. 31 %, p <0.025). ROC analysis showed CESM performance was
better than LE alone (AUC 0.933 vs. 0.848, p <0.05).
Conclusion: This preliminary study demonstrates the additional clinical
utility of CESM in symptomatic patients. Its potential use in other clinical
settings (e.g. screening of high-risk women) requires evaluation.
P15
Comparative study of radiation dose between tomosynthesis and
standard compression views in mammography
Alice Bannister*, Julie Scudder
Guys and St Thomas’ NHS Foundation Trust, London, UK
Breast Cancer Research 2015, 17(Suppl 1):P15
Introduction: Objectives were a comparative study of the radiation dose
of two-view digital breast tomosynthesis (DBT) and two-view spot
compression views in a symptomatic breast service.
Methods: Two hundred patients were included in the study, 100 who
had undergone two-view spot compression views and 100 two-view DBT.
DBT was carried out using GE Seno Claire with an iso-dose setting and
grid system. A retrospective computer-based search of patients in the
two categories was undertaken and the accumulative dose for each
technique was identified and recorded, as was the thickness of the breast
from the original cc mammogram projection. The percentage variance of
dose between DBT and spot compression views was calculated according
to breast thickness.
Results: The mean accumulative glandular dose for the whole group
regardless of breast thickness was 2.84 for DBT compared with 3.50 for
spot compression views. In this patient population, the AGD was lower
for DBT than for FFDM in 64 % of the patients. When patients were
categorized according to breast thickness, the accumulative glandular
dose of DBT was on average 22 % less than spot compression
mammography with a reduction ranging from 53 to 1 %. There was no
evidence in this study that dose reduction with DBT significantly
increased with increasing breast thickness.
Conclusion: The radiation dose of patients undergoing two-view DBT on
average showed a significant reduction compared to two-view spot
compression views. The dose reduction may be attributed to the grid and
iso-dose technology used in the selected DBT system.
P16
Positive predictive value of mammographic features on digital breast
tomosynthesis
Bhavna Batohi*, Juliet Morel, Reema Wasan, Asif Iqbal, David Evans,
Jane Goligher, Michael Michell, Clare Peacock, Rumana Rahim,
Keshthra Satchithananda
King’s College Hospital, London, UK
Breast Cancer Research 2015, 17(Suppl 1):P16
Introduction: Digital breast tomosynthesis (DBT) is increasingly used for
the further assessment of mammographically detected abnormalities due
to its superior specificity compared with 2D digital mammography
(2DDM). In this study we evaluate the positive predictive value (PPV) of
mammographic features on DBT and assessment categories as per the
Royal College of Radiologists (RCR) breast group classification system.
Methods: Women recalled following routine screening mammograms
underwent bilateral 2DDM and DBT over an 18-month period.
Experienced screening radiologists prospectively evaluated each case,
documenting mammographic sign, size and classification according to
the RCR breast group guidelines. DBT findings and final pathology were
then correlated.
Results: A total of 759 abnormalities were included. On DBT, 221 (29 %)
were normal. Of the remaining 538, there were 207 circumscribed
masses, 89 spiculate masses, 156 microcalcifications, 35 distortions and 51
asymmetric densities. Final histology revealed 204 malignant and 334
benign lesions. The PPVs were 97.7 % for spiculate masses, 65.7 % for
distortions, 35.8 % for microcalcifications, 16.9 % for circumscribed
masses and 5.8 % for asymmetric densities.
Conclusion: DBT allows more accurate assessment of mammographic
lesions without the impedance of overlying tissues. Spiculate masses
have the highest PPV on both 2DDM and DBT. Although the PPV for
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asymmetric densities appears relatively low on DBT, this is still nearly
twice that of 2DDM. Better understanding of the likelihood of
tomographic signs indicating malignancy will increase the value of DBT.
P18
Initial outcome of contrast-enhanced spectral mammography in lesion
characterisation in the mammographically dense breast
Zeiad Hussain*, Peter Duggan, Julie Scudder, Sarah McWilliams
Guys and St Thomas NHS Trust, London, UK
Breast Cancer Research 2015, 17(Suppl 1):P18
Introduction: The accuracy of mammography is limited in the dense
breast. Contrast-enhanced spectral mammography (CESM) is a relatively
new alternative with promising results. The aim of this study is to assess
the sensitivity, specificity, positive predictive value (PPV) and negative
predicative value (NPV) of CESM in the detection and characterization of
breast lesions.
Methods: Retrospective review of the prospectively maintained database
of patients who underwent CESM over a period of 6 months. The
sensitivity, specificity, PPV and NPV of CESM were assessed against the
histopathology result. In a subgroup of eight patients, the CESM outcome
was also compared to MRI scan results. In addition, patients’
demographics and correlation with mammography and ultrasound
outcomes were obtained.
Results: Twenty-four patients (23 female) underwent CESM over a
6-month period. CESM was found to have a sensitivity of 76 %, specificity
of 66 %, PPV of 93 % and NPV of 66 %. The median maximal lesion
dimension (MMLD) on CESM was 29 mm. In a subgroup of eight patients
MRI was also performed where the MMLD on MRI was 22 mm and on
CEM was 20 mm. MRI accurately diagnosed all malignant lesions
(8/8) while CEM demonstrated a false negative results in 2/8 patients.
In five of the 11 patients who initially had mammography and four of
the 19 patients who initially had ultrasound scan demonstrating
indeterminate lesions, CEM correctly characterised the lesions.
Conclusion: CESM is a promising and affordable technique in the
assessment of suspicious lesions in the mammographically dense breast.
CEM has a good sensitivity, specificity, PPV and NPV.
P19
A perceptual aid to delineating the extent of potential mammographic
abnormalities
Arul Selvan1*, Yan Chen2, Alastair Gale2
1Sheffield Hallam University, Sheffield, UK; 2Loughborough University,
Loughborough, UK
Breast Cancer Research 2015, 17(Suppl 1):P19
Poster presentation: Being able to accurately determine the extent of a
possible malignancy on a mammogram is an important task as this can
affect the potential follow-up surgical treatment that a woman receives
after breast screening. It is known that this can be a difficult task,
particularly where the lesion has diffuse abnormalities. A potential
computer-aided approach is to employ hierarchical clustering-based
segmentation (HCS) and this interactive educational exhibit dynamically
demonstrates this technique. HCS is an unsupervised segmentation
process that when applied to an image yields a hierarchy of
segmentations based on image pixel dissimilarities and so can be used to
highlight areas in the mammographic image to aid interpretation.
A set of 15 known difficult FFDM mammographic cases were selected
from PERFORMS case sets where expert radiologists had previously
delineated the extent of various abnormalities. Regions of interest (ROI)
around these abnormalities were extracted from the DICOM images and
processed using HCS algorithms resulting in a set of paired original
mammographic ROI images and related HCS processed ROI images. In
the exhibit these paired images are presented and delegates interactively
select which of the pair they think best identifies abnormality extent. The
original expert delineated abnormality is then provided as feedback. Over
the course of the conference, data will be collected on how useful the
HCS approach has been found and this information fed back to
participants. The learning objectives are to demonstrate the potential of
this approach in increasing the perceptual recognition of abnormal
appearances.
P20
Diagnostic implications of digital breast tomosynthesis in symptomatic
patients
Sanjeeva Ramasundara1,2*, Lorraine Tucker1,2, Matthew Wallis1, Peter Britton1,
Penny Moyle1, Kethryn Taylor1, Ruchi Sinnatamby1,2, Alan Freeman1,
Matthew Gaskarth1, Fiona Gilbert1,2
1Cambridge University Hospital, Cambridge, UK; 2University of Cambridge,
UK
Breast Cancer Research 2015, 17(Suppl 1):P20
Introduction: The purpose of this study was to assess the diagnostic
performance/utility of digital breast tomosynthesis (DBT) in symptomatic
patients in a multidisciplinary clinical setting.
Methods: The study was registered as a Cambridge University Hospital
(CUH) service evaluation audit. Patients from the CUH symptomatic breast
clinic from October 2014 to February 2015 were included in the study.
Patients were included as clinic workflow permitted and DBT and full field
digital mammography (FFDM) (SenoClaire, GE) were interpreted
prospectively. Image quality of the DBT and 2D synthetic images were
rated on a 5-point scale compared to FFDM. The imaging findings were
graded on both FFDM and DBT as normal, benign, indeterminate,
suspicious or malignant. Patients were clinically examined and additional
ultrasound was carried out as appropriate. FFDM and DBT findings were
correlated with the ultrasound findings and when performed to
histopathology.
Results: A total of 134 patients were included. Eighty-five per cent of the
synthetic images were considered qualitatively similar or better than the
FFDM images. Nineteen lesions were graded as indeterminate, 10 lesions
were graded as suspicious and six lesions were graded as malignant on
FFDM, whereas three lesions were graded as indeterminate, four lesions
were graded as suspicious and 14 lesions were graded as malignant on
DBT. Seventy-nine per cent of the indeterminate lesions on FFDM were
downgraded accurately by DBT and 16 % were upgraded accurately
by DBT. There was one false negative and three false positives with FFDM
and DBT.
Conclusion: DBT helps characterise indeterminate lesions more
accurately compared with FFDM in the symptomatic setting.
P21
A review of BRCA gene carrier demographics in Wales
Tom Evans1*, Jenny Long1, Georgina Devenish1,2, Mike Lewis3, Damian Bailey3,
Kate Gower Thomas2,3, Alexandra Murray1,4
1Cardiff and Vale University Health Board, Cardiff, UK; 2Breast Test Wales,
Cardiff, UK; 3University of South Wales, Pontypridd, UK; 4All Wales Genetics
Service, Cardiff, UK
Breast Cancer Research 2015, 17(Suppl 1):P21
Introduction: Women who inherit a mutated copy of the BRCA-1 or
BRCA-2 genes have a higher lifetime risk of developing breast cancer.
There have been no large epidemiological studies looking at BRCA-
positive patients in the UK.
Methods: Across the All Wales Genetics Service, individuals with
confirmed BRCA mutation, since formal testing began (1995) to 1 January
2015, were included–identified from a prospectively gathered database.
Genetics case notes were obtained and retrospective analysis carried out.
Results: A total of 419 females with mean age 47 (19−81) were included
in the study. Of these, 206 were identified using diagnostic testing with
the remaining 213 undergoing predictive testing. Of the predictive group
who subsequently had cancer, 18 (78 %) developed breast cancer. Seven
(39 %) had wide local excision (WLE), six (33 %) had single mastectomy
while the remaining five (28 %) had bilateral mastectomies as their
primary operation. Five of the predictive group (22 %) had ovarian
cancer. Of these, four (80 %) went on to have prophylactic breast surgery
too. Of the 13 patients who underwent WLE or single mastectomy, four
(31 %) went on to have completion risk reduction mastectomies (RRM).
From the remaining 190 individuals in the predictive group with
no cancer diagnosis, 102 (54 %) have had no risk reduction surgery,
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32 (17 %) RRM only, 31 (16 %) BSO only and 25 (13 %) underwent both
procedures.
Conclusion: There is variation in the surgical management of BRCA
positive patients in Wales. This has implications for service allocation and
demands for screening for these high-risk patients.
P22
Audit of high prevalent breast screening recall rates: Torbay Hospital
Alexander Crowther*, Rebecca Green
Torbay DGH, Torquay, UK
Breast Cancer Research 2015, 17(Suppl 1):P22
Introduction: The target percentage of women recalled after prevalent
round breast screening is <7 % with minimum standards <10 %. Torbay
Hospital’s prevalent round recall is high at 11.4 %. We plan to assess
patterns of recall by category to see if any particular reason for recall
could be decreased.
Methods: Retrospective audit of 12 months of prevalent round recalls
March 2013-February 2014. All age groups were included. Each recall was
grouped into one/more of the following categories: calcification, well-
defined mass, ill-defined mass, asymmetric density, distortion, clinical,
other. We will calculate the proportion of recalls per group that proved to
be malignancy and assess to see if any category was a poor predictor of
malignancy. All histology proven malignancies from 2012/13 and 2014/15
will also be categorised by group.
Results: There were 215 recalls for ages 49–69, 15 proven malignancies.
77% of Ill-defined mass, 22% of distortion and 10% of calcifications
recalled proved to be malignant and are the strongest predictors of
malignancy. Well-defined mass and asymmetric density had 0%
malignancy rates and accounted for 129 (59.4 %) of prevalent recalls.
Thirteen clinical recalls (1.4 %) were also 0 % for malignancy but beyond
the control of the screening service. Further audit was performed looking
at the proven malignancies from 2012/13 and 2014/15, which showed a
total of 33 malignancies with 13 calcifications, 17 ill-defined masses, one
asymmetry, one distortion and one clinical recall.
Conclusion: A high proportion of recalls (60 %) are for well-defined mass
and asymmetric density which have poor predictive outcome. These
groups are potential areas to decrease recall rates. A total 1.4 % of
clinical recalls are beyond the control of the screening service, which
would bring prevalent recalls to a compliant level of 10 %.
P23
Outcome of ultrasound of the mammographically normal contralateral
breast in patients recalled to the screening assessment clinic
Preet Hamilton*, Simon Lowes, Sheetal Sharma, Alicia Wright, Alice Leaver
Gateshead Hospitals NHS Trust, Gateshead, UK
Breast Cancer Research 2015, 17(Suppl 1):P23
Introduction: Women diagnosed with breast cancer are at increased risk
of contralateral breast cancer; some of these cancers will be synchronous
and mammographically occult (M1). Ultrasound may detect M1 breast
cancers but also benign lesions that necessitate needle testing, conferring
additional patient morbidity that could be termed ‘over investigation’.
Local guidelines for ultrasound of the M1 contralateral breast vary
between units. We present a retrospective audit of contralateral M1
breast ultrasound within our screening assessment clinics.
Methods: Screening and pathology hospital databases of 2013 and 2014
identified records of 331 women with screen-detected breast cancer.
Descriptive statistics were performed.
Results: All 331 women underwent ipsilateral breast ultrasound; 288 (87
%) underwent ultrasound of their contralateral mammographically normal
(M1) breast. Six contralateral breast lesions were needle sampled: four B2
lesions, two B3 without atypia. No subsequent breast cancer has been
detected in any of these patients to date.
Conclusion: Two years of routine contralateral ultrasound has yielded no
cancers but also very few benign biopsies. Ongoing audit and discussion
of risk/benefit to patients is indicated.
P24
Impact of index of multiple deprivation and ethnicity on breast
screening uptake in the North West of England
Jayeshwaraj Bhola1*, Anil Jain1,2, Philip Foden1
1The University of Manchester, UK; 2The Nightingale Centre and Genesis
Prevention Centre, University Hospital of South Manchester NHS Foundation
Trust, Manchester, UK
Breast Cancer Research 2015, 17(Suppl 1):P24
Introduction: The aim was to investigate the impact of index of multiple
deprivation (IMD) and ethnicity on breast cancer screening uptake in the
North West of England.
Methods: Data for screening uptake rates were collected from 2005 to
2014 using data from the North West Breast Screening Units and the
annual breast screening statistics reports. These were correlated with the
IMD published in 2007 and 2010. The uptake rates were also correlated
with ethnicity data obtained from the Census 2011. Then, the results for
ethnicity were adjusted for IMD.
Results: Both prevalent and incident uptake rates have declined from
2005/06 to 2013/14. Deprivation was shown to negatively correlate with
breast screening uptake in all rounds, the strongest correlation being
with prevalent screening rounds (IMD 2007 p = 0.005 and 2010 p =
0.016). The incident round negative correlation was IMD 2007 p = 0.002
(significant) and IMD 2010 p = 0.163 (not significant). For ethnicity, the
Caucasian population showed a positive correlation while Asian, a
negative correlation. This was more significant in the Pakistani and
Bangladeshi groups. Interestingly, when the results were adjusted for
deprivation, ethnicity did not show a significant correlation with uptake
rates.
Conclusions: Our results clearly show that the more deprived an area,
the lower the breast screening uptake rate. Moreover, the higher the
proportion of Asian in a population, the lower the uptake rates and this
is more significant in the Pakistani and Bangladeshi group compared to
the Indian and Chinese. Overall the impact is most marked in the
prevalent round.
P25
Does tomosynthesis increase confidence in grading the suspicious
appearance of a lesion? An audit of cancers diagnosed in the
assessment clinic using tomosynthesis: initial experience at Avon Breast
Screening Unit
Gillian Clark*, Alexandra Valencia
Avon Breast Screening Unit, Bristol Breast Care Centre, North Bristol NHS
Trust, Bristol, UK
Breast Cancer Research 2015, 17(Suppl 1):P25
Introduction: Tomosynthesis is a new technology that is being used
increasingly to evaluate the breast for assessment in the UK. It has,
however, been approved as a screening tool in the United States, Canada
and several European countries. We implemented tomosynthesis in the
Assessment Clinic at Avon Breast Screening Unit (ABSU) last year as
recommended by the NHSBSP. A retrospective audit of 134 consecutive
cancers diagnosed from 9 June 2014 to 31 December 2014 was
performed. The aim was to evaluate whether tomosynthesis gives
additional information to increase the grading of mammographic features
of a lesion seen on initial screening mammography and increase the
assessor’s confidence.
Result: A total of 134 cancers were reviewed. Sixty-six lesions were
graded the same on screening mammography and the assessment
tomosynthesis. Thirty-six were M5 lesions at screening and assessment.
Thirty M3 or M4 lesions remained unchanged. One patient had an M3
lesion that was downgraded. Three patients had incidental cancers found
on ultrasound. Sixty-four lesions were upgraded with tomosynthesis.
Forty-four of 64 M3 or M4 lesions were upgraded to tomosynthesis 5.
Twenty of 64 were upgraded from M3 to tomosynthesis 4. The
morphology of the lesions upgraded was spiculated 30/64, 7/64
distortions and 7/64 ill-defined densities. Thirty-one of 44 tomosynthesis
5 lesions measured 10 mm or less.
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Conclusion: Tomosynthesis is excellent at showing the spiculate nature
of lesions, upgrading the appearance of a lesion from M3 and M4 to
tomosynthesis 5 which increases the assessor’s confidence during the
assessment clinic. It is also excellent in helping identify small suspicious
lesions of 10 mm or less. However, ultrasound should always be
performed in addition to tomosynthesis as lesions may rarely be
downgraded.
P26
An audit of marker placement in stereotactic guided biopsy
Jane Prady1,2*, Lucy Hill1,3, Alison Gray1, Alison Gilchrist1
1South East of Scotland Breast Screening Service, Edinburgh, UK; 2Queen
Margaret University, Edinburgh, UK; 3British Society of Breast Radiology,
Edinburgh, UK
Breast Cancer Research 2015, 17(Suppl 1):P26
Introduction: Anecdotal evidence suggests that there is a greater
incidence of marker migration using large volume sampling techniques in
stereotactic guided breast biopsies.
Methods: Prospective study of 130 biopsies with markers done between
June and December 2014. Markers more than 10 mm from the target
lesion were considered migrated. The aim of the audit was to quantify
the number of markers migrating, distance and direction of migration
and conditions under which markers migrate.
Results: A total of 12.3 % had migrated markers: 10.7 % from use of
the Bard Encor system and 1.5 % from use of the Bard Vacora system. The
greatest marker migration occurred using a latero-medial approach. The
majority of migrated markers were deeper than the target lesion. Marker
migration was significantly greater using the Encor system within lucent
breast tissue. Firstly, further audit is required incorporating lesion size,
routine vacuuming of the cavity before deployment of marker, specific
sequencing of marker films, correlation of compressed breast thickness
and target depth, clinical impact of marker migration and possible
development of expanding marker. Secondly, the breast screening service
should provide guidelines regarding distances, thresholds and targets for
marker migration.
Conclusion: This audit found that marker migration occurred
predominantly within lucent breast tissue and using the latero-medial
approach when using the Bard Encor system.
P27
Handheld ultrasound-guided 20 mm basket Intact breast lesion
excision system biopsy for excision of benign breast lesions
Simon Lowes*, Alice Leaver, Alice Townend, Jackie Westgarth, Peter Newton,
Dianne Hemming, Alan Redman
Gateshead Hospitals NHS Trust, Gateshead, UK
Breast Cancer Research 2015, 17(Suppl 1):P27
Introduction: In selected patients, our Unit has recently moved from
handheld ultrasound-guided vacuum-assisted core biopsy (VACB)
piecemeal acquisition of tissue to the handheld Intact Breast Lesion
Excision System (Intact). Intact removes a single piece of tissue,
potentially allowing radiologists to excise the entire lesion as well as
allowing pathologists to visualise lesion architecture more easily and to
calculate margins. We evaluated our early experience of excising benign
or likely benign breast lesions using the 20 mm Intact.
Methods: Prospective data collection was performed on all patients
undergoing handheld ultrasound-guided Intact excision under local
anaesthetic in 2014 and 2015, which comprised 19 lesions in 18 female
patients aged 29−73.
Results: The device was technically straightforward to operate and well-
tolerated by patients with no significant complications. Handheld needle
orientation was difficult within dense glandular tissue (only one
acquisition is possible per needle), but improved with increased operator
experience. Achieving adequate analgesia required higher quantities of
local anaesthetic than for the equivalent VACB. Pathologists found
specimens easier to interpret than VACB samples. In all cases adequate
excision was completed sonographically at one outpatient appointment,
but in six cases a second Intact biopsy and/or a VACB was required to
complete that excision, with extra cost implications. In two patients with
M3 microcalcification the Intact pathology demonstrated ductal
carcinoma in situ, leading to surgical wide local excision.
Conclusion: Our early experience shows Intact as a reliable and effective
tool for handheld diagnostic and/or therapeutic excision of selected
breast lesions.
P28
The 3.5-year to 13.5-year follow up of 137 lesions of uncertain malignant
potential (B3 lesions) diagnosed by vacuum-assisted biopsy alone
Karen Mullin*, Anne Turnbull, Sharma Puri, Mark Bagnall
Royal Derby Hospital, Derby, UK
Breast Cancer Research 2015, 17(Suppl 1):P28
Introduction: Vacuum-assisted biopsy (VAB) was introduced in Derby in
2001, as the second procedure after 14g core biopsy. We present 3.5-year
to 13.5-year follow up of cases where B3 lesions have been managed
with VAB alone.
Methods: The NBSS and local BASO databases were searched from
January 2002 to December 2011 for all cases with B3 histopathology, a
VAB procedure and no surgery. Screening and symptomatic women were
included.
Results: There were 137 women who met the criteria. The pathologies
found are presented in Table 1. The cases where atypia was found were
individually discussed at MDT to ensure that the abnormal feature had
either been excised or very well sampled. Only one breast cancer has
developed at the same site in a woman who had 5 mm calcification excised
at VAB. This lobular cancer was identified 4 years later at recall from annual
surveillance. Five other cancers have developed in the 137 cases, one
contralaterally and four different lesions in different sites in the same breast.
Conclusion: This study provides further evidence for the safety of the
use of VAB alone in the diagnosis of B3 lesions in the longer term.
P29
Quantitative study: should vacuum-assisted biopsy be the first biopsy
approach in breast interventional techniques in stereotactic guided
microcalcifications rather than 14 gauge core needle biopsy?
Anuma Shrestha*, Louise Wilkinson, Rosalind Given-Wilson, Judi Curtis
St George’s Healthcare NHS Trust, London, UK
Breast Cancer Research 2015, 17(Suppl 1):P29
Introduction: Stereotactic guided 14 gauge core needle biopsy (14GCNB)
and vacuum-assisted biopsy (VAB) are the two commonly used biopsy
methods for obtaining an accurate diagnosis for microcalcifications.
Table 1(abstract bcr3790)
Pathology Initial biopsy Final pathology
CSL 39 37
Papillary lesion, no atypia 51 50
Papillary lesion, atypia 2 0
CCC atypia/flat epithelial atypia 12 0
ADH/apocrine atypia/AIDEP 9 1
Lobular neoplasia 6 5
Mucocoele-like lesion 5 0
Other B3 atypia 5 0
Fibroepithelial lesion 2 0
B2 4 40
Fibroadenoma 0 3
B1 2 0
VAB only 0 1
Total 137 137
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Retrospective review of 399 patients who underwent biopsy for breast
microcalcification during screening assessment from April 2012 to March
2013 was used to evaluate the performance and cost-effectiveness of
both methods.
Methods: The repeat biopsy rate, diagnostic accuracy, time taken and
cost of both methods was calculated. Microsoft Excel (2010) and SPSS 22
were used for statistical analysis.
Results: The repeat biopsy rate for 14GCNB was 10 % and VAB was 6 %.
Specificity, PPV and NPV were all 90 % or higher when compared against
post-surgical final diagnosis in both methods. The sensitivity of VAB was
93.75 % vs. 71.88 % for 14GCNB for first biopsy. There was no significant
difference in procedure time between two methods (p = 0.291). VAB
necessitated almost double the rate of clip deployment compared with
14GCNB. The cost of VAB would be £69,922 greater than 14GCNB if used
as the first-line biopsy method in this series.
Conclusion: This study found VAB to have higher sensitivity than
14GCNB. There was also a trend for lower repeat biopsy rate, higher
diagnostic accuracy and lower surgical upgrade with VAB. If VAB had
been used as the first biopsy method for microcalcifications, the cost
would have been significantly higher. 14GCNB is a cost-effective but less
sensitive first biopsy method for selected microcalcifications.
P30
Safety of vacuum-assisted biopsy/mammatome guided, non-operative
management of B3 lesions without atypia: a 7-year follow-up study
Alex Wilkins1,2*, Peter Kneeshaw1, Penelope McManus1, Kartikae Grover1,
Caroline Bradley1, Ayesha Rahman1, Anne Hubbard1
1Castle Hill Hospital, Cottingham, UK; 2Hull York Medical School, Hull, UK
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Introduction: B3 management balances safe treatment of potential
malignancy against the morbidity of surgical excision of benign lesions.
Vacuum-assisted biopsy (VAB) increases diagnostic accuracy, removing
some lesions entirely without surgery. Few follow-up data are available to
assess the safety and effectiveness of this approach.
Methods: A total of 215 patients with B3 biopsies without atypia were
identified using Labcentre histopathology codes at a single centre.
Hospital and NBSS records were analysed to identify patients who were
treated with VAB and mammographic surveillance alone and to
determine outcome over a follow-up period of 52−149 months (median
85). Local Labcentre and regional Pathlinks histopathology records were
independently checked. Mammograms of ipsilateral re-presentations were
reviewed by a consultant radiographer and consultant radiologist to
determine whether lesions developed at the site of B3 biopsy.
Results: Twenty per cent had excision biopsy (42/215) of which <5 %
(2/42) contained carcinoma. A total of 144 patients had VAB which
identified 30 high-risk cases analysed separately (DCIS, B4 or atypia). In
total, 114 B3 lesions without atypia (on either core biopsy or VAB) were
followed mammographically after VAB with no surgical intervention. Four
patients re-presented to the service with malignancy; 37, 38, 41 and
67 months after VAB. Sixty-one per cent (69/114) of individuals were
screened locally 2012−2015.
Conclusion: VAB of B3 biopsies without atypia appears to be safe with
no representations in the first 3 years and overall carcinoma and DCIS
incidence of 3.5 % over 7 years (4/114). National guidance on B3 lesion
management is required.
P31
Safety of vacuum-assisted biopsy/mammatome guided, non-operative
management of B3 lesions with atypia: a 7-year follow-up study
Alex Wilkins1,2*, Peter Kneeshaw1, Penelope McManus1, Kartikae Grover1,
Caroline Bradley1, Ayesha Rahman1, Anne Hubbard1
1Castle Hill Hospital, Cottingham, UK; 2Hull and East Yorkshire Medical
School, Hull, UK
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Introduction: B3 management balances safe treatment of potential
malignancy against the morbidity of surgical excision of benign lesions.
Vacuum-assisted biopsy (VAB) increases diagnostic accuracy, removing
some lesions entirely without surgery. Few follow-up data are available to
assess the safety and effectiveness of this approach.
Methods: A total of 129 patients with B3 VAB with atypia were identified
using Labcentre histopathology codes at a single centre. Hospital and
NBSS records were analysed to identify patients treated with VAB and
mammographic surveillance alone and to determine outcome over a
follow-up period of 52−142 months (median 85).
Results: Ten per cent progressed directly to surgery (13/129). A total of
116 were followed mammographically after VAB with no surgical
intervention (49 ADH, 2 ALH, 21 LCIS, 44 atypia (not otherwise specified)).
Nine patients re-presented to the service with invasive carcinoma (six
ipsilateral) and two with DCIS (both ipsilateral) between 12 and 80
months. The ipsilateral re-presentation rate was highest for ADH (5/49)
and LCIS (2/21). In the absence of ADH or LCIS, the only ipsilateral
representation was one low-grade DCIS, 62 months after VAB.
Conclusion: Re-presentation with ipsilateral carcinoma following VAB
excision for ADH and LCIS is comparable to surgical excision for ADH and
LCIS. National guidance is required.
P32
Use of WHO checklist in interventional breast radiological procedures
Trupti Kulkarni1,2*, Andrew O’Connor1
1University Hospital Aintree, Liverpool, UK; 2Clatterbridge Breast Unit, Wirral,
UK
Breast Cancer Research 2015, 17(Suppl 1):P32
Introduction: Increasing awareness of safety in healthcare provision has
resulted in incorporation of risk-reducing strategies. The WHO checklist is
now increasingly being used by interventional radiology. Is it relevant for
the interventional breast radiologist?
Methods: A questionnaire for assessing awareness and use of the WHO
checklist used for surgical procedures (or a modified checklist) was
devised. Responses were collected and analysed via Survey Monkey.
Results: Eighty-one complete responses were received and analysed. In
total, 93.83 % were aware of the WHO checklist; 83.95 % worked in
departments where this was used by IR; and 46.91 % used the checklist
individually or as a department. The list was locally devised in 43.21 %.
Of those who did not employ use of the list, 27.16 % had considered its
use. A total of 24.69 % had never considered using it. Fifty-four per cent
opined it was relevant to a therapeutic vacuum-assisted procedure with
various individual procedures having scores ranging from 12 to 47 %.
Adherence to CQC standards was cited as the reason for use of the
checklist. Naysayers quoted increase in time required and poor work flow
as reasons for not using it.
Conclusion: Breast radiological intervention procedures, although low
risk and with low complications, remain health interventions. An adverse
event should not be a necessary trigger for change of practise. Opinion
on use of additional safeguards such as an intervention checklist, while
divided, suggested that a modified checklist is called for in complex
procedures involving recall of patient at a different date, multiple
radiologists involved and therapeutic procedures under vacuum guidance.
P33
Breast biopsy in patients on anti-coagulants: is new guidance needed?
Trupti Kulkarni1,2*, Andrew O’Connor1
1University Hospital Aintree, Liverpool, UK; 2Clatterbridge Breast Unit, Wirral,
UK
Breast Cancer Research 2015, 17(Suppl 1):P33
Introduction: Patients on anti-coagulation requiring breast biopsies are
more at risk of bleeding. Newer anti-coagulants may not have a method
for quantifying coagulation unlike the INR for warfarin. Also, some of
these such as dabigatran do not have antidotes and rely on the body’s
ability to excrete the drug which may be altered by renal function. There
are no up-to-date national guidelines on breast biopsy in such patients.
Methods: A questionnaire for assessing practise of breast biopsy in
patients on various anti-coagulants was devised. Responses were
collected and analysed via Survey Monkey.
Results: Seventy-eight complete responses were received and analysed.
Thirty-eight per cent of respondents said they had local guidelines while
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45 % used BSBR guidelines 2012. Sixty-three per cent would refer back to
the GP/specialist in cases of warfarinised patients,14 % in cases of
patients on clopidogrel and only 1 % of those on aspirin. Eighty-eight per
cent of respondents did not have a policy for dabigatran and
rivaroxaban. Practise was different in screening and symptomatic groups
in 7 % due to the site of screening units away from A/E. Unit policy in
warfarinised patients requiring vacuum-assisted biopsy (VAB) was not
available to 38 %. Anecdotally, a number of radiologists reported that
they would not perform VAB in patients on clopidogrel.
Conclusion: There is a wide variation in practise while performing
biopsies in patients on anti-coagulation including the newer anti-
coagulants.
P34
Role of mammographic templates in managing ever increasing
workloads
Anne Nielsen Moody*, Maggie Fletcher, Nisha Sharma
Leeds Teaching Hospitals NHS Trust, Leeds, UK
Breast Cancer Research 2015, 17(Suppl 1):P34
Introduction: A breast imaging report is a key component of the breast
cancer diagnostic process. The report must be clear and concise to avoid
ambiguity and confusion. However, substantial variation in the
information provided in a breast imaging report is not uncommon to see.
We sought to develop a report template containing a summary of all
essential information pertinent to the surgeons and the radiologists.
Methods: Breast surgeons and radiologists were consulted as to what
was required in a report and they stated breast density, correlation with
clinical findings, lesion characteristics, R1−R5 category, site and size of
lesion, and is clinical area of concern biopsied. A retrospective audit of 30
breast imaging reports of recently diagnosed carcinomas between
October 2014 and January 2015 were reviewed to see if these were
recorded.
Results: Ten per cent of reports did not mention breast density. The
most frequent information provided is lesion size (ultrasound 100 %,
mammography 73 %). Correlation with referral was unclear in 10 %, R1
−R5 category not given in 3 %. Site of lesion was not provided in 3 %.
Seven per cent of the reports were 3−4 pages long, described as
confusing and difficult to read by the two data extractors. Thirty per cent
of reports were not separated into mammography/ultrasound/biopsy
sections. There were 23 different ways of characterising lesions on
mammography and 24 on ultrasound.
Conclusion: The audit highlighted the need for a breast reporting
template that met the needs of the clinicians to ensure the relevant facts
were included to further improve the patient pathway.
P35
Local experience of referral for breast assessment resulting from
incidental findings on CT and PET-CT studies over a 5-year period
Richard Sidebottom*, Jean Lee, Shaheel Bhuva, Vaishali Parulekar
Oxford Breast Imaging Centre, Oxford University Hospitals NHS Trust,
Oxford, UK
Breast Cancer Research 2015, 17(Suppl 1):P35
Introduction: Incidental findings of breast abnormalities from cross-
sectional imaging (CT and PET-CT) are a relatively common source of
referral for breast assessment at our unit. We sought to describe and
quantify our local experience of these referrals and to determine which
cross-sectional imaging findings were more predictive of malignancy.
Methods: Retrospective review using radiology information system
searches for mammography referrals resulting from CT and PET-CT scan
findings performed over a 5-year period (July 2010−July 2015) in Oxford
University Hospitals NHS Trust. Studies in patients with known active
breast malignancy were excluded. Cross-sectional imaging characteristics
of the abnormalities were collected including CT enhancement, PET
avidity, size and shape. Assessment imaging features, subsequent biopsy
and clinical outcomes were recorded.
Results: A total of 126 patients were assessed as a result of incidental
breast abnormalities. Thirty-six of 126 (29 %) were subsequently found to
have breast malignancy (CT 28/110, 25 % and PET CT 8/16, 50 %). Size,
shape and CT enhancement features will be presented. Lesions with high
avidity on PET-CT scans were more likely to be primary breast cancer on
biopsy (83 % SUVmax >2.5). Of 36 breast malignancies identified, three
patients underwent mastectomy surgery, 10 had wide local excision and
20 had non-surgical management. Three patient outcomes are unknown
at the time of writing.
Conclusion: Referrals arising from incidental abnormalities identified on
cross-sectional imaging have a high yield for breast malignancy (29 %).
Incidental PET findings, while less often a route of referral, have the
highest likelihood of identifying a malignant lesion.
P36
Do bone scans add to CT in detecting skeletal metastases in breast
cancer staging?
Anuradha Anand1*, Lekha Potti2, Geoff Naisby1, Sheetal Sharma2,
Alan Redman2
1James Cook University Hospital, Middlesbrough, UK; 2Queen Elizabeth
Hospital, Gateshead, UK
Breast Cancer Research 2015, 17(Suppl 1):P36
Introduction: Recent studies have questioned the value of bone scans
(BS) in staging breast cancer when a CT chest, abdomen and pelvis is
also performed. We retrospectively reviewed breast cancer staging CTs
and BS performed within 2 months of each other, to see if BS identified
more skeletal metastases than CT.
Methods: Our study was performed at the breast screening unit at
Queen Elizabeth Hospital, Gateshead (QE) and the symptomatic breast
unit at James Cook University Hospital (JCUH), Middlesbrough.
Experienced radiologists blinded to primary BS reports retrospectively
assessed CTs performed for primary breast cancer, known recurrence or
to explain symptoms of pain. They then reviewed the same patient’s BS.
CT and BS were marked positive, negative or indeterminate for skeletal
metastases.
Results: Combined data from both units yielded 253 cases in total. CT
and BS concurred in 217 cases. Of the remaining 36, CT identified skeletal
metastases in five where BS was negative and two where BS was
indeterminate. CT excluded metastases in 23 which were indeterminate
on BS. BS confirmed or excluded metastases in five cases where CT was
indeterminate and identified metastases in only one case which was
negative on CT. This lesion proved to be benign and hence BS was false
positive in this case.
Conclusion: BS does not detect more skeletal deposits than CT in the
initial assessment or follow-up of breast cancer. CT should be used as the
first-line investigation for skeletal and visceral metastasis and BS reserved
for problem-solving.
P37
A comparative study of pathological and prognostic differences in
DCIS between Asian and Caucasian women
Raeesa Patel1*, Anil Jain1,2, Philip Foden1
1The University of Manchester, UK; 2The Nightingale Centre and Genesis
Prevention Centre, Manchester, UK
Breast Cancer Research 2015, 17(Suppl 1):P37
Introduction: The aim was to compare the histopathological and
prognostic differences in DCIS between age-matched Asian and
Caucasian female patients.
Methods: Data related to presentation, histopathology, prognosis and
treatment of DCIS were gathered from 48 women from the Asian Breast
Cancer Database at the Nightingale Centre, all of whom had begun with
an initial diagnosis (at biopsy) of DCIS. These were compared with age-
matched Caucasian patients, also diagnosed with DCIS at the time of
biopsy. The total study included 96 patients.
Results: Out of 48 Asian women more presented symptomatically (25,
52.1 %) compared to Caucasian women (13, 27.1 %), p = 0.012. Asian
women had a larger mean value in regards to tumour size (28.48 mm)
compared to Caucasian women (21.59 mm), and more progressed from
an initial diagnosis of DCIS, to a final diagnosis of DCIS with an invasive
component (12.5 % compared to 2.1 %), p = 0.05. However, differences in
the average Van Nuys Prognostic Index score were not statistically
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significant in Asian (7.13) and Caucasian (7.51) patients, p = 0.236.
Interestingly, significantly more Asian women were treated with
mastectomy (47.9 %) compared to Caucasian women (22.9 %), p = 0.015.
Conclusion: Asian women presented with a larger tumour size, more
progressed to a diagnosis of invasive carcinoma, and more had
mastectomies compared to Caucasian women. Since fewer Asian women
are presenting via the screening programme, education and awareness of
breast cancer and screening needs to be increased in Asian women to
increase their screening uptake rates.
P38
Comparison of prognostic indices in symptomatic and screen-detected
invasive breast cancer in Asian and Caucasian women
Andrew Steele1*, Anil Jain1,2, Navneet Randhawa1, Philip Foden1, Julie Morris1
1The University of Manchester, UK; 2The Nightingale Centre and Genesis
Prevention Centre, Manchester, UK
Breast Cancer Research 2015, 17(Suppl 1):P38
Introduction: In the UK, ethnic minority groups have reported lower
awareness of breast screening and have presented with breast cancer
symptoms later than Caucasian women. Our study compared prognostic
indices in symptomatic and screen-detected breast cancer between Asian
and Caucasian patients.
Methods: Of the 310 Asian women diagnosed with breast cancer
between 1999 and 2014 in the Asian Breast Cancer Database, 217 with
invasive cancer were selected (57 screen-detected and 160 symptomatic).
Data on invasive tumour size, grade, lymph node status and NPI were
compared with age and mode-matched Caucasian breast cancer patients.
Results: Asian symptomatic women had larger invasive tumours (median
25.0 mm, IQR 17.1−35.8 mm), compared with Caucasian patients (median
17.0 mm, IQR 12.0−26.4 mm) (p <0.001); higher proportions of grade 3
tumours (64.4 %) (p = 0.007) and with more than one lymph node
involved (46.2 %) (p = 0.004), compared with Caucasian patients (48.8 %
and 30.0 % respectively); worse NPI scores (median 4.6, IQR 4.3−5.6),
compared with Caucasian patients (median 4.3, IQR 3.3−4.7) (p <0.001);
and higher proportions with poor prognosis (33.8 %), compared with
Caucasian patients (11.9 %) (p <0.001). Multivariable analysis showed
invasive grade and tumour size were statistically significant independent
discriminators with lymph node status as borderline significant. However,
there was no statistically significant difference between the ethnic groups
for screen-detected invasive tumours.
Conclusion: Prognostic indices in Asian women were worse in
symptomatic breast cancer, but similar in screen-detected invasive cancer,
compared with age-matched Caucasian women. Greater initiatives need
to be implemented to promote breast cancer awareness, education and
screening among the Asian ethnic minorities.
P39
Prospective study looking at CT staging for metastases in early breast
cancer
Michelle McMahon*, Nisha Sharma, David Dodwell
The Leeds Teaching Hospitals, NHS Trust, Leeds, UK
Breast Cancer Research 2015, 17(Suppl 1):P39
Introduction: Practice is variable nationally with no agreed guidelines for
performing CT staging of asymptomatic patients with a new diagnosis of
breast cancer. We have devised a new proforma for performing staging
CT in asymptomatic women with high-risk early breast cancer. In our unit,
600 cancers are diagnosed/year.
Methods: Prospective audit identifying patients eligible for CT staging
based on our proforma over a 12-month period were identified at the
breast cancer MDT. A staging scan of the chest, abdomen and pelvis was
performed. CT results and clinic letters were reviewed. Criteria:
asymptomatic patients diagnosed with new breast cancer requiring
staging (T4, inflammatory breast cancer or tumour which extends into the
chest wall, skin, or both, fixed nodal disease, arm oedema, nodal disease
in SCF; T3, tumour >50 mm clinically, radiologically or pathologically; ≥4
positive nodes at surgery; part of clinical trial involvement or extensive
residual disease at surgery after NACT).
Results: Forty patients were referred for a CT staging, four patients did
not proceed. Indications: 26 (65 %) had four or more metastatic nodes,
six (15 %) T3, eight (20 %) T4. 20/36 (56 %) had no evidence of
metastatic disease; 8/36 (22 %) had definite metastases identified (four,
>4 nodes, three T4 and one T3); 8/36 (22 %) had indeterminate findings.
In three cases the diagnosis of metastatic disease contributed to the
decision not to proceed with surgery. No negative impact on treatment
was reported in the indeterminate cases.
Conclusion: The new proforma for guiding staging CT scans has reduced
the number of overall scans performed with a relatively high pick-up rate
of 22 %.
P40
Breast pain in the over 40s: impact on imaging
Trupti Kulkarni*, Andrew O’Connor
Aintree University Hospital, Liverpool, UK
Breast Cancer Research 2015, 17(Suppl 1):P40
Introduction: Current practice in our unit as agreed with the local Cancer
Network Group is for women over 40 years presenting with breast pain
and with a normal clinical examination to have a mammogram. NICE
recommends no imaging in this group of patients. The aim was to
measure workload impact from current practice, and assess diagnostic
yield.
Methods: Retrospective audit of imaging and biopsy in female patients
over 40 years, presenting with breast pain, and who had normal clinical
examination.
Results: A total of 100 patients, aged 40−65, from 30 clinics over 3
months, 2014. Eighty normal mammograms. Seven of these had
ultrasound for focal tenderness or probable glandular tissue, all of which
were normal. Twenty abnormal mammograms: eight calcifications, six
asymmetry, five discrete masses, one implant rupture. Total imaging
workload: nine requests for previous imaging from elsewhere, eight
further mammographic views, 11 ultrasounds, two stereo core biopsies
(benign), one ultrasound-guided FNA followed by core biopsy
(malignant). Yield: one cancer (25 mm grade 2 invasive ductal, negative
sentinel lymph node).
Conclusion: Workload is appreciably impacted by breast pain
investigations. The final diagnosis was often delayed because of the wait
for pathology results and previous imaging, increasing patient anxiety.
The cancer detection rate number is too low for significance, but
nevertheless compares favourably to screening. After discussion with
clinicians it was decided to keep to our current practice as a means of
opportunistic screening, particularly as our unit is in an area of poor
screening uptake.
P41
Breast cancer in women under 35 years
Kate Hunter*, Deirdre Boyle, John Kavanagh, Yvonne Hanhauser,
Elizabeth Connolly, Sylvia O’Keeffe
St James’s Hospital, Dublin, Ireland
Breast Cancer Research 2015, 17(Suppl 1):P41
Introduction: Breast cancer is rare in young women under 35 years;
however, it can present a diagnostic challenge. This study was
undertaken to determine the presentation of breast cancer in young
women and the role of imaging including the predictive value in
determining tumour size.
Methods: All breast cancer diagnoses in women aged ≤35 years from
2006 to 2014 were identified. Data were then extracted from PACS and
EPR. Analysis was performed on Microsoft Excel. Paired t tests were used
to assess the accuracy of imaging in predicting final pathological tumour
size.
Results: Seventy patients with 74 presentations of carcinoma were
included. Mean age 31 years (SD = 3.7). Of 73 examination scores (E): 7 %
(5/73) were screen detected, 52 % (38/73) were E2−3 and 38 % (28/73)
were suspected (E4−5). At ultrasound, 16 % (12/74) were U3 and 82 %
(61/74) were suspected to be malignant (U4−5). Seventy-four per cent
(51/69) had a mammogram score M4−M5. Seventy-five per cent (50/67)
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of patients were ACR density of 3−4. At MRI (42/70), tumour size
correlated with final tumour size on pathology (N = 24, Pearson R 0.45).
There was no significant difference between MR estimates of size and
final tumour size (t = −0.88, p = 0.39). In contrast, there was a significant
difference between US size estimates and final pathology (N = 43, t =
−2.56, p <0.05).
Conclusion: Clinical examination has a low PPV in young women with
ultrasound demonstrating a superior performance. However, 16 % of
cancers were unsuspected at ultrasound. An important finding is the
usefulness of MR in defining tumour size, suggesting it should be
performed in all young patients.
P42
’Peace of mind’? Demand for breast imaging investigation following
normal clinical examination: establishing the patient benefits and
service implications for a symptomatic service
Miaad Al-Attar*, Lubna Bashir, Lisa Grosvenor, Diane Lister, Elizabeth Denton,
Moin Hoosein, Lakshmi Sundaram, Gayle McDonald, Niki Hartley
Breast Care Centre, Glenfield Hospital, UHL, Leicester, UK
Breast Cancer Research 2015, 17(Suppl 1):P42
Introduction: In the symptomatic service, we noted that requests for
imaging after normal examination appeared to be significantly increasing
but not improving cancer detection. We aimed to identify demand for
imaging following normal clinical examination and their incidence of cancer.
Methods: Our unit underwent clinic reorganisation, with the consultant
surgeon as primary clinical assessor in February 2014. We carried out a
retrospective audit, choosing a month prior and post service
reorganisation. All patients referred to imaging with normal clinical
examination (P = 1) were included. We recorded demographics, presenting
complaint, requestor, findings and biopsies outcomes.
Results: Pre consultant involvement, 576 patients were seen and 175
referred with P = 1 (30 %). A total of five biopsies (3 % of referred) were
performed retrieving two malignancies (1 % of referred). Post reorganisation,
771 patients were seen and 308 referred to imaging with P = 1 (40 %).
A total of 32 biopsies were performed (10 % of referred) with three
malignancies (<1 % of referred). In this group only one patient was <40
years old. All cancers were invasive ductal (B5b). All malignancies were in
areas of presenting concern. There was a significant increase in workload
with decreasing sensitivity of radiology and clinical examination post
reorganisation. The background incidence of malignancy was low and
stable.
Conclusion: There is increasing demand on imaging for patients with
normal clinical examination unrelated to clinical seniority. Cancers are
present even with normal clinical examination and patient’s initial clinical
concern proved to be an important predictor. Careful scrutiny of the
patient’s presenting symptom may allow detection of all cancers.
P43
The radiologist in the fast track breast clinic: the invisible man (woman)
Nicholas Ridley1*, Charlotte Jones2, Nathan Coombs2, Sarah Taylor1
1Breast Unit, Great Western Hospital, Swindon, UK; 2Department of Surgery,
Great Western Hospital, Swindon, UK
Breast Cancer Research 2015, 17(Suppl 1):P43
Introduction: During a visit to radiology a GP expressed surprise when
she discovered that all the breast imaging and biopsies were done by
radiologists. She assumed these were done by the surgical team. This led
us to review the surgical letters to GPs to see if the radiologist’s
contribution was acknowledged.
Methods: We reviewed 20 surgical letters from the initial fast-track
appointment to GPs about patients with a proven cancer. All imaging
and biopsies were performed by a consultant radiologist or radiographer.
Results: Seventeen (85 %) letters were written by a consultant breast
surgeon and three (15 %) by breast registrars. Only one (5 %) letter
mentioned radiological involvement and two described the biopsies as
‘we performed’ giving the impression that the biopsy had been
performed by the surgical team. In 17 the description of the imaging and
biopsy was neutral.
All of the letters, however, were judged to be excellent in terms of
information to the GP.
Conclusion: Many medical professionals outside of the breast team are
unaware of the role of the radiologist. The radiologist, despite doing all the
imaging and biopsies in our clinic (which is the case in many units around
the country), was essentially invisible in 19 of 20 of the letters we
reviewed. We need to debate how we promote the contribution of the
radiologist. This could be by reviewing the GP letter template with our
surgical colleagues or by promoting the role of radiology to GPs, clinicians,
medical students and the general public.
P44
Follow-up imaging of breast symptomatic patients: a waste of
radiologist time?
Diana Dalgliesh*, Alison Smith, Anjum Mahatma
Royal United Hospital, Bath, UK
Breast Cancer Research 2015, 17(Suppl 1):P44
Introduction: The NHSBSP does not recommend early recall following
assessment of screen-detected abnormalities. Symptomatic patients in our
breast clinic may be invited to return for repeat imaging. A survey of
repeat imaging in our symptomatic breast clinic was undertaken to
understand whether we can justify reducing the number of patients
recalled and to gauge associated anxiety levels.
Methods: We identified 71 consecutive patients attending an imaging
appointment from 1 February 2013 who had a repeat imaging
recommendation. Patients were asked to complete a questionnaire. We
recorded reason for recall, imaging interval, imaging outcome, and
feedback from questionnaires.
Results: One patient did not attend. Mean interval between initial and
repeat imaging: 4−16 weeks. Fifty-five episodes classified R1/R2 at initial
imaging; 11 R3; four R4. Outcomes: 68 % were discharged; 11 % were
invited for a third imaging appointment and all were then discharged; 13 %
had a benign biopsy; 7 % returned to the surgical clinic for management of
their benign symptom. Twenty-three questionnaires were completed − one
patient was ‘very anxious’ about repeat imaging, seven patients were ‘mildly
anxious’, 10 were ‘relieved’, six were ‘not bothered’.
Conclusion: Repeat imaging did not yield any diagnoses of malignancy.
All patients were eventually discharged with a benign outcome. We can
justify reducing follow-up imaging of our symptomatic patients in line
with guidelines for screening assessments. Radiologist time may be better
directed towards meeting the symptomatic breast 2-week wait standard.
Cite abstracts in this supplement using the relevant abstract number,
e.g.: Dalgliesh et al.: Follow-up imaging of breast symptomatic patients:
a waste of radiologist time?. Breast Cancer Research 2015, 17(Suppl 1):P44
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